A new collaboration between Fuzionaire Diagnostics, McGill University, and Montreal Neurological Institute and Hospital seeks to better detect and treat neurological diseases.
The collaboration will utilize Fuzionaire's radiopharmaceutical discovery platform to create radiotracers that localize and image abnormal brain tissue. The technology can radiofluorinate molecules in seconds and at ambient temperature, according to the company.
The goal is to produce noninvasive diagnostic imaging tests for Alzheimer's disease, Parkinson's disease, and traumatic brain injury.
